Entries of Hartmann, R. W. on the publication server

Hartmann, R. W., Batzl, C., Mannschreck, Albrecht and Pongratz, T. (1990) Unequal Aromatase Inhibition by the Enantiomers of 3-Cylcohexyl-3-(4-aminophenyl)-2,6-piperidinedione. In: Holmstedt, Bo and Frank, H. and Testa, B., (eds.) Chirality and biological activity: proceedings of an international symposium, Tübingen, Federal Republic of Germany, April 5 - 8, 1988. Liss, New York, p. 185. ISBN 0-471-56226-2. Fulltext not available.

Schwarz, W., Hartmann, R. W., Engel, J., Schneider, M. R. and Schönenberger, Helmut (1989) Ester derivatives of the mammary-tumor-inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane. Journal of cancer research and clinical oncology 115 (2), pp. 161-165. Fulltext not available.

Hartmann, R. W., Batzl, C., Mannschreck, Albrecht and Seydel, J. K. (1989) New Aromatase Inhibitors. QSAR and Evaluation of Mammary Tumor Inhibiting Activity. In: van der Groot, H. and Domany, G. and Pallos, L. and Timmerman, H., (eds.) Trends in medicinial chemistry '88. Elsevier, Amsterdam, p. 821. Fulltext not available.

Hartmann, R. W., Schwarz, W., Schneider, M. A., Engel, J. and Schönenberger, Helmut (1988) D-18954. Drugs of the Future 13, pp. 720-721. Fulltext not available.

Hartmann, R. W. (1985) TETRAMETHYLHES. Drugs of the Future 10, pp. 48-49. Fulltext not available.

Engel, J., Hartmann, R. W. and Schönenberger, Helmut (1983) METAHEXESTROL. Drugs of the Future 6, pp. 413-419. Fulltext not available.

Hartmann, R. W., Schönenberger, Helmut and Wrobel, K. H. (1982) 3,4-Bis(3'-hydroxyphenyl)hexane - a new mammary tumor-inhibiting compound. Studies on the mechanism of action on the DMBA-induced, hormone-dependent mammary tumor of the rat. Journal of cancer research and clinical oncology 103 (3), pp. 241-254. Fulltext not available.

Kranzfelder, G., Hartmann, R. W., Angerer, E. von, Schönenberger, H. and Bogden, A. E. (1982) 3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compound. Journal of cancer research and clinical oncology 103 (2), pp. 165-180. Fulltext not available.